» Articles » PMID: 9600906

Crystallographic Comparison of the Estrogen and Progesterone Receptor's Ligand Binding Domains

Overview
Specialty Science
Date 1998 May 30
PMID 9600906
Citations 150
Authors
Affiliations
Soon will be listed here.
Abstract

The 2.8-A crystal structure of the complex formed by estradiol and the human estrogen receptor-alpha ligand binding domain (hERalphaLBD) is described and compared with the recently reported structure of the progesterone complex of the human progesterone receptor ligand binding domain, as well as with similar structures of steroid/nuclear receptor LBDs solved elsewhere. The hormone-bound hERalphaLBD forms a distinctly different and probably more physiologically important dimer interface than its progesterone counterpart. A comparison of the specificity determinants of hormone binding reveals a common structural theme of mutually supported van der Waals and hydrogen-bonded interactions involving highly conserved residues. The previously suggested mechanism by which the estrogen receptor distinguishes estradiol's unique 3-hydroxy group from the 3-keto function of most other steroids is now described in atomic detail. Mapping of mutagenesis results points to a coactivator-binding surface that includes the region around the "signature sequence" as well as helix 12, where the ligand-dependent conformation of the activation function 2 core is similar in all previously solved steroid/nuclear receptor LBDs. A peculiar crystal packing event displaces helix 12 in the hERalphaLBD reported here, suggesting a higher degree of dynamic variability than expected for this critical substructure.

Citing Articles

Antiproliferative Role of Natural and Semi-Synthetic Tocopherols on Colorectal Cancer Cells Overexpressing the Estrogen Receptor β.

Falsetti I, Palmini G, Zonefrati R, Vasa K, Donati S, Aurilia C Int J Mol Sci. 2025; 26(5).

PMID: 40076925 PMC: 11900421. DOI: 10.3390/ijms26052305.


Octamethylcyclotetrasiloxane (D4) lacks endocrine disruptive potential via estrogen pathways.

Borgert C, Burgoon L Arch Toxicol. 2025; .

PMID: 39976757 DOI: 10.1007/s00204-024-03896-y.


Lucidin from Outperforms FDA-Approved Lapatinib as a Potential Multitargeted Candidate for Breast Cancer Signalling Proteins.

Aloqbi A, Alahdal H, Alqosaibi A, Alnamshan M, Al-Dhuayan I, Al-Eidan A Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861131 PMC: 11768784. DOI: 10.3390/ph18010068.


A lesson in symmetry.

Boncler M Nat Struct Mol Biol. 2024; 31(12):1813.

PMID: 39604562 DOI: 10.1038/s41594-024-01437-w.


Integrated Molecular Docking and Experimental Analysis of Ni(II) Proline Dithiocarbamate Cytotoxicity in MCF-7 Breast Cancer Cells.

Prihantono P, Jarre S, Raya I, Santi S, Paramita K, Syamsu S Asian Pac J Cancer Prev. 2024; 25(10):3481-3487.

PMID: 39471014 PMC: 11711347. DOI: 10.31557/APJCP.2024.25.10.3481.


References
1.
Beato M, Herrlich P, Schutz G . Steroid hormone receptors: many actors in search of a plot. Cell. 1995; 83(6):851-7. DOI: 10.1016/0092-8674(95)90201-5. View

2.
Katzenellenbogen J, Katzenellenbogen B . Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem Biol. 1996; 3(7):529-36. DOI: 10.1016/s1074-5521(96)90143-x. View

3.
Mangelsdorf D, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K . The nuclear receptor superfamily: the second decade. Cell. 1995; 83(6):835-9. PMC: 6159888. DOI: 10.1016/0092-8674(95)90199-x. View

4.
Perlmann T, Umesono K, Rangarajan P, Forman B, Evans R . Two distinct dimerization interfaces differentially modulate target gene specificity of nuclear hormone receptors. Mol Endocrinol. 1996; 10(8):958-66. DOI: 10.1210/mend.10.8.8843412. View

5.
Horlein A, Naar A, Heinzel T, Torchia J, Gloss B, Kurokawa R . Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 1995; 377(6548):397-404. DOI: 10.1038/377397a0. View